7478 completed, 2620 recruiting, 2252 unknown, 1683 terminated. 5450 Phase 2, 3808 Not applicable, 3249 Phase 1, 1512 Phase 3, 273 Phase 4.
Follow Urogenital Neoplasms: new trials by email Literature Review of Urogenital Neoplasms trials Research Report on Urogenital Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications | Phase 2 | Withdrawn | Institut Paoli-Calmettes | 2032-01-01 | 2026-10-14 | |
| PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria (a) Training and (b) Supported risk assessment - Prostate Cancer, Risk Assessment | Not applicable | Not yet recruiting | Ahmadu Bello University | 89 | 2029-03-01 | 2026-07-29 |
| Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer AI Uro-Cam - Bladder Cancer | Not applicable | Not yet recruiting | Chinese University of Hong Kong | 60 | 2028-07-31 | 2026-07-22 |
| Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors Exercise and dietary recommendations - Ovarian Cancer | Not applicable | Not yet recruiting | Oncare Madrid | 32 | 2028-05-01 | 2026-10-08 |
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 500 | 2028-03-01 | 2025-03-30 |
| REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency) - Metastatic Castration-Resistant Prostate Cancer, mCRPC | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 192 | 2027-06-28 | 2026-09-30 |
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| Development of Systems and Education for Cervical Cancer Prevention (DOSE-CC) DOSE-CC Intervention: Educational Sessions - Cervical Cancer Screening, Cervical Cancer | Not applicable | Not yet recruiting | Boston Medical Center | 80000 | 2027-05-01 | 2025-11-10 |
| Topical Curcumin for HPV Related Cervical Disease Curcumin C3 Complex, Placebo - Neoplasm Cervix | Phase 2 | Not yet recruiting | Lisa Flowers | 200 | 2027-04-01 | 2026-05-08 |
| PITCH - Impacting Hereditary Cancer Testing Genetic testing education video - Ovarian Cancer, Genetic Testing | Not applicable | Not yet recruiting | Rachel Miller | 200 | 2027-04-01 | 2026-09-10 |
| Cancer Awareness Among Syrian Migrants PMT-Based Cancer Screening Educational Intervention, PMT-Based Cancer Screening Education Program - Breast Cancer Screening, Cervical Cancer Screening | Not applicable | Not yet recruiting | Toros University | 30 | 2027-03-09 | 2026-10-15 |
| Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans Survey - Head and Neck Cancer, Prostate Cancer | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 94 | 2027-03-01 | 2026-10-01 |
| Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain Biospecimen Collection, Low-Dose Aspirin, Patient Observation - Endometrial Carcinoma | Phase 4 | Not yet recruiting | Mayo Clinic | 20 | 2027-02-12 | 2026-08-05 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 27 | 2027-02-01 | 2026-10-01 |
| Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer losartan, Paclitaxel - Platinum Resistant Ovarian Cancer | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 27 | 2027-02-01 | 2026-09-22 |
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| DK222 Study at Hopkins [18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2027-01-31 | 2026-09-29 |
| iCCARE Project #4: Grounded Theory Study of the Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men Diagnosed With Prostate Cancer Interviews - Prostate Cancer | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-01-31 | 2026-10-06 |
| HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients With Persistent Hypogonadism After ADT for Treatment of Localized Prostate Cancer Clomiphene Citrate 25mg - Prostate Cancer | Phase 2 | Not yet recruiting | University of Nebraska | 83 | 2027-01-31 | 2026-10-20 |
Showing 20 of 16759. Sign in to see all of them.
Prostatic Neoplasms (6443) · Ovarian Neoplasms (3258) · Uterine Cervical Neoplasms (2241) · Carcinoma, Renal Cell (1956) · Urinary Bladder Neoplasms (1723) · Endometrial Neoplasms (1387) · Breast Neoplasms (1263) · Neoplasms (1092) · Kidney Neoplasms (956) · Fallopian Tube Neoplasms (827) · Carcinoma, Ovarian Epithelial (784) · Carcinoma, Non-Small-Cell Lung (694) · Colorectal Neoplasms (665) · Neoplasm Metastasis (632) · Lung Neoplasms (584)
Urogenital Diseases (16744) · Neoplasms by Site (16680) · Neoplasms (15667) · Genital Diseases (12992) · Male Urogenital Diseases (10897) · Female Urogenital Diseases and Pregnancy Complications (10679) · Female Urogenital Diseases (10678) · Genital Diseases, Male (6832) · Genital Neoplasms, Male (6794) · Genital Diseases, Female (6596) · Genital Neoplasms, Female (6539) · Prostatic Diseases (6456) · Neoplasms by Histologic Type (4522) · Urologic Diseases (4406)
Paclitaxel (618) · Carboplatin (605) · Cisplatin (475) · Docetaxel (430) · pembrolizumab (429) · Gemcitabine (369) · Bevacizumab (362) · Radiotherapy (347) · Magnetic Resonance Spectroscopy (318) · Nivolumab (265) · Prednisone (263) · enzalutamide (221) · Cyclophosphamide (204) · Specimen Handling (195) · Leuprolide (190)
National Cancer Institute (NCI) (664) · M.D. Anderson Cancer Center (378) · Memorial Sloan Kettering Cancer Center (329) · University Health Network, Toronto (175) · AstraZeneca (167) · Pfizer (146) · Gynecologic Oncology Group (145) · Mayo Clinic (138) · Dana-Farber Cancer Institute (126) · Novartis Pharmaceuticals (116) · Merck Sharp & Dohme LLC (115) · Jonsson Comprehensive Cancer Center (99) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (95) · GlaxoSmithKline (94) · Duke University (92)
United States (8150) · China (1713) · Canada (1475) · France (1319) · United Kingdom (1144) · Italy (1064) · Spain (934) · Germany (811) · Netherlands (674) · Australia (668) · South Korea (652) · Belgium (647) · Denmark (428) · Poland (412) · Japan (410)
Lei Li, M.D. (38)
PMID 37185961, PMID 37146227, PMID 37407274, PMID 41276263, PMID 34350976, PMID 31401903, PMID 35170751, PMID 27238653, PMID 28410911, PMID 24722180, PMID 33270906, PMID 41698328, PMID 25577718, PMID 33465252, PMID 33538338, PMID 36884035, PMID 36971688, PMID 38421243, PMID 38421252, PMID 39695768, PMID 40966692, PMID 19097774, PMID 19238149, PMID 22894553, PMID 25712310, PMID 25819287, PMID 27626136, PMID 29272162, PMID 30633128, PMID 32203306, PMID 32994091, PMID 33526329, PMID 37526095, PMID 38320143, PMID 39462179, PMID 16394300, PMID 20818904, PMID 22747660, PMID 23228299, PMID 23922302, PMID 25592642, PMID 26961146, PMID 27626365, PMID 29342393, PMID 30207593, PMID 30380365, PMID 32379297, PMID 32499241, PMID 32779730, PMID 33058158
2023 (132), U10CA027469 (95), U10CA180868 (80), 2017 (79), 2016 (69), 2025 (66), 2019 (61), P30CA033572 (59), 2018 (58), 2015 (47), P30CA016672 (45), P30CA043703 (44), 2008 (42), 2014 (42), 2009 (39)